Log in to your Inderes Free account to see all free content on this page.
Glycorex Transplantation
1.22 SEK
+0.83 %
Less than 1K followers
GTAB B
NGM Main Regulated
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.83 %
-15.28 %
-22.04 %
-23.27 %
-35.28 %
-40.49 %
-67.72 %
-90.59 %
-87.98 %
Glycorex Transplantation is active in biotechnology. The company conducts research, development and marketing in the field of organ transplantation. The company's main product enables transplants regardless of the blood type of the donor or recipient. Transplantation using the company's product is carried out on a global level. Glycorex Transplantation was founded in 1996 and has its headquarters in Lund.
Read moreMarket cap
96.2M SEK
Turnover
26.79K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
22.5.
2026
Interim report Q1'26
28.5.
2026
General meeting '26
28.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Glycorex Transplantation (GTAB B): First ABO-incompatible organ transplantion in Morocco with Glycosorb® ABO
Glycorex Transplantation (GTAB B): Enters distribution agreement in Greece for Glycosorb® ABO in the field of transfusion and transplantation
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio